The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

The Role of the Intestinal Hormones Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide 2 (GLP-2) in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Humans

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05391581

Acronym

GA-17

Enrollment

Registered

2022-05-26

Start date

2022-01-13

Completion date

2023-02-07

Last updated

2023-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Flow

Keywords

Gut hormones, GIP, GLP-2, Physiology

Brief summary

This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and GLP-2 with the use of two novel receptor antagonists GIP(3-30)NH2 and GLP-2(3-33) in healthy individuals.

Detailed description

Each participant will attend eight independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo), subcutaneous injection (hormon/placebo) and oral ingestion (glucose/water). On experimental day A-C, an intravenous infusion of saline, GIP(3-30)NH2, or GLP-2(3-33), respectively, starts at time point -20 minutes. On experimental day D-F, the same infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes. On experimental days G-H, a subcutaneous injection of either GIP or GLP-2 at time point 0 minutes is performed (positive control) during saline infusion and oral water ingestion. MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.

Interventions

OTHERGIPR antagonist / study tool

Selective antagonist of the GIPR, GIP(3-30)NH2

OTHERGLP-2R antagonist / study tool

Selective antagonist of the GLP-2R, GLP-2(3-33)

OTHERPlacebo

Saline

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Intervention model description

Single blind, placebo controlled, randomized, crossover study

Eligibility

Sex/Gender

MALE

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* No first degree relatives with diabetes * BMI 20-27 kg/m2

Exclusion criteria

* Not MRI-compatible implants * Claustrophobia * Diabetes * Abnormal kidney or liver function * Anemia * Planned weight loss or change in diet * Hypertension * Other conditions that could be expected to affect the primary or secondary outcomes

Design outcomes

Primary

Measure	Time frame	Description
Redistribution of splanchnic blood flow (functional MRI)	90 minutes	Flow in mesenteric superior artery

Secondary

Measure	Time frame	Description
GLP-2 levels	90 minutes	Blood sample (pmol/L)
GIP(3-30)NH2 levels	90 minutes	Blood sample (nmol/L)
GLP-2(1-33) levels	90 minutes	Blood sample (nmol/L)
CTX (bone resorption marker)	90 minutes	Blood sample
P1NP (bone formation marker)	90 minutes	Blood sample
Glucose	90 minutes	Blood sample (mmol/L)
C-peptide	90 minutes	Blood sample (pmol/L)
GIP levels	90 minutes	Blood sample (pmol/L)
Glucagon	90 minutes	Blood sample (pmol/L)
Heart rate	90 minutes	Beats/minute
Flow in coeliac trunk	90 minutes	Functional MRI estimated blood flow
Flow in hepatic artery	90 minutes	Functional MRI estimated blood flow
Flow in portal vein	90 minutes	Functional MRI estimated blood flow
Liver oxygen content	90 minutes	Functional MRI estimated oxygenation
Insulin	90 minutes	Blood sample (pmol/L)

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026